CY1121673T1 - Εξουδετερωση αντισωματων στις κυριες εξωτοξινες tcda και tcdb της λοιμωξης clostridium difficile - Google Patents
Εξουδετερωση αντισωματων στις κυριες εξωτοξινες tcda και tcdb της λοιμωξης clostridium difficileInfo
- Publication number
- CY1121673T1 CY1121673T1 CY20191100596T CY191100596T CY1121673T1 CY 1121673 T1 CY1121673 T1 CY 1121673T1 CY 20191100596 T CY20191100596 T CY 20191100596T CY 191100596 T CY191100596 T CY 191100596T CY 1121673 T1 CY1121673 T1 CY 1121673T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tcdb
- clostridium difficile
- neutralizing antibodies
- difficile infection
- tcda
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title abstract 3
- 239000002095 exotoxin Substances 0.000 title abstract 2
- 231100000776 exotoxin Toxicity 0.000 title abstract 2
- 208000037384 Clostridium Infections Diseases 0.000 title 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 title 1
- 206010054236 Clostridium difficile infection Diseases 0.000 title 1
- 241000193163 Clostridioides difficile Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91091—Glycosyltransferases (2.4)
- G01N2333/91097—Hexosyltransferases (general) (2.4.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535532P | 2011-09-16 | 2011-09-16 | |
| US201261638731P | 2012-04-26 | 2012-04-26 | |
| PCT/GB2012/052222 WO2013038156A1 (en) | 2011-09-16 | 2012-09-10 | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121673T1 true CY1121673T1 (el) | 2020-07-31 |
Family
ID=46881094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100596T CY1121673T1 (el) | 2011-09-16 | 2019-06-05 | Εξουδετερωση αντισωματων στις κυριες εξωτοξινες tcda και tcdb της λοιμωξης clostridium difficile |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10752676B2 (enExample) |
| EP (2) | EP3617227A3 (enExample) |
| JP (3) | JP6152107B2 (enExample) |
| KR (1) | KR20140063825A (enExample) |
| CN (2) | CN108424449A (enExample) |
| AU (1) | AU2012307157B2 (enExample) |
| BR (1) | BR112014006175B1 (enExample) |
| CA (1) | CA2848611A1 (enExample) |
| CL (1) | CL2014000491A1 (enExample) |
| CO (1) | CO6930310A2 (enExample) |
| CY (1) | CY1121673T1 (enExample) |
| DK (1) | DK2758432T3 (enExample) |
| EA (1) | EA032475B1 (enExample) |
| EC (1) | ECSP14013316A (enExample) |
| ES (1) | ES2729278T3 (enExample) |
| HK (1) | HK1199463A1 (enExample) |
| HR (1) | HRP20190917T1 (enExample) |
| HU (1) | HUE043661T2 (enExample) |
| IL (1) | IL231167A0 (enExample) |
| LT (1) | LT2758432T (enExample) |
| MX (1) | MX2014002769A (enExample) |
| PE (1) | PE20141547A1 (enExample) |
| PH (1) | PH12014500456A1 (enExample) |
| PL (1) | PL2758432T3 (enExample) |
| PT (1) | PT2758432T (enExample) |
| SG (2) | SG10201701055WA (enExample) |
| SI (1) | SI2758432T1 (enExample) |
| TN (1) | TN2014000101A1 (enExample) |
| WO (1) | WO2013038156A1 (enExample) |
| ZA (1) | ZA201402760B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012307157B2 (en) * | 2011-09-16 | 2017-08-03 | Ucb Pharma S.A. | Neutralising antibodies to the major exotoxins TcdA and TcdB of Clostridium difficile |
| EP2925362A4 (en) * | 2012-11-28 | 2016-07-20 | Cnj Holdings Inc | ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE |
| US10226523B2 (en) * | 2013-04-22 | 2019-03-12 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile vaccine and methods of use |
| US9926345B2 (en) | 2014-02-18 | 2018-03-27 | The Hospital For Sick Children | Compositions and methods for treating or preventing Clostridium infection |
| US9717711B2 (en) | 2014-06-16 | 2017-08-01 | The Lauridsen Group | Methods and compositions for treating Clostridium difficile associated disease |
| WO2016178773A1 (en) * | 2015-04-06 | 2016-11-10 | Saureus, Inc. | System and method for detecting clostridium difficile toxins |
| WO2016168392A1 (en) * | 2015-04-15 | 2016-10-20 | Medimmune, Llc | Methods for treating clostridium difficile infection and associated disease |
| EP4074730A1 (en) | 2015-06-24 | 2022-10-19 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies with tailored affinity |
| EP3344276B1 (en) | 2015-09-03 | 2020-04-22 | The Board of Regents of the University of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| AR106230A1 (es) | 2015-10-02 | 2017-12-27 | Hoffmann La Roche | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso |
| USD864160S1 (en) | 2016-12-06 | 2019-10-22 | Samsung Electronics Co., Ltd. | Audio device |
| WO2018111662A1 (en) * | 2016-12-14 | 2018-06-21 | Merck Sharp & Dohme Corp. | Human genetic markers associated with response to treatments that target clostridium difficile toxin b |
| CN110607314B (zh) * | 2019-10-31 | 2022-09-23 | 四川农业大学 | 一种TcdB RBD基因、重组RBD蛋白和应用 |
| CN111763263A (zh) * | 2020-07-09 | 2020-10-13 | 宁夏医科大学 | 一种艰难梭菌抗原及多克隆抗体的制备方法和检测试剂盒 |
| CN112500484B (zh) * | 2021-01-29 | 2021-06-08 | 迈杰转化医学研究(苏州)有限公司 | 一种抗trop2抗体及其应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| ZA929870B (en) | 1991-12-23 | 1993-08-18 | Duphar Int Res | Adjuvants |
| KR100278157B1 (ko) | 1992-06-25 | 2001-01-15 | 장 스테판느 | 보조약을 함유하는 백신 조성물 |
| SK117395A3 (en) | 1993-03-23 | 1996-11-06 | Smithkline Beecham Biolog | Vaccine composition and manufacturing process thereof |
| ATE195740T1 (de) | 1993-11-17 | 2000-09-15 | Om Pharma | Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| EP1167378B1 (en) | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
| WO1998016247A1 (en) | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| JP5220248B2 (ja) | 1997-08-29 | 2013-06-26 | アンチジェニックス・インコーポレイテッド | アジュバントｑｓ−２１および賦形剤としてポリソルベートまたはシクロデキストリンを含む組成物 |
| DE69815692T2 (de) | 1997-09-05 | 2004-04-29 | Glaxosmithkline Biologicals S.A. | Öl in wasser emulsionen mit saponinen |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| AU2003299527A1 (en) * | 2002-06-17 | 2004-06-07 | Jimmy D. Ballard | Mutant of clostridium difficile toxin b and methods of use |
| DK1567117T3 (da) * | 2002-11-26 | 2012-05-21 | Univ Chicago | Forebyggelse og behandling af mikrobe-medierede epitelsygdomme |
| ES2374068T3 (es) | 2002-12-03 | 2012-02-13 | Ucb Pharma, S.A. | Ensayo para identificar células productoras de anticuerpos. |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| PL1644412T5 (pl) | 2003-07-01 | 2019-01-31 | Ucb Biopharma Sprl | Modyfikowane fragmenty Fab przeciwciała |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| DK2270045T3 (en) * | 2004-02-06 | 2015-04-07 | Univ Massachusetts | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| BRPI0517592B1 (pt) | 2004-12-27 | 2016-03-15 | Huntsman Corp Australia Pty Ltd | formulação agroquímica sólida, método para preparar a mesma, e, formulação de concentração de suspensão |
| CA2592015A1 (en) | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
| US8852600B2 (en) * | 2006-06-08 | 2014-10-07 | The Rockefeller University | Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| CN101842387B (zh) * | 2007-09-26 | 2014-05-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
| CN101980723A (zh) * | 2008-02-28 | 2011-02-23 | 3M创新有限公司 | 艰难梭菌芽孢的抗体及其用途 |
| ES2793008T3 (es) * | 2008-06-25 | 2020-11-12 | Novartis Ag | Anticuerpos estables y solubles que inhiben VEGF |
| JP6063122B2 (ja) | 2008-09-26 | 2017-01-18 | ユセベ ファルマ ソシエテ アノニム | 生物学的産物 |
| EP2405940B1 (en) * | 2009-02-20 | 2021-08-04 | Secretary of State for Health and Social Care | Antibodies to clostridium difficile toxins |
| ES2757675T3 (es) * | 2010-04-15 | 2020-04-29 | Progenics Pharm Inc | Anticuerpos para el tratamiento de la infección y enfermedad asociada a Clostridium difficile |
| WO2012055030A1 (en) * | 2010-10-25 | 2012-05-03 | National Research Council Of Canada | Clostridium difficile-specific antibodies and uses thereof |
| US9815889B2 (en) * | 2011-08-02 | 2017-11-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Antibodies for prevention and treatment of diseases caused by clostridium difficile |
| AU2012307157B2 (en) * | 2011-09-16 | 2017-08-03 | Ucb Pharma S.A. | Neutralising antibodies to the major exotoxins TcdA and TcdB of Clostridium difficile |
| UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| US20150259402A1 (en) * | 2012-10-19 | 2015-09-17 | Evec Inc. | Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201411420D0 (en) * | 2014-06-26 | 2014-08-13 | Ucb Biopharma Sprl | Antibody constructs |
| US9107906B1 (en) * | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
-
2012
- 2012-09-10 AU AU2012307157A patent/AU2012307157B2/en not_active Expired - Fee Related
- 2012-09-10 HU HUE12761789A patent/HUE043661T2/hu unknown
- 2012-09-10 DK DK12761789.2T patent/DK2758432T3/da active
- 2012-09-10 WO PCT/GB2012/052222 patent/WO2013038156A1/en not_active Ceased
- 2012-09-10 PT PT12761789T patent/PT2758432T/pt unknown
- 2012-09-10 HK HK14113105.9A patent/HK1199463A1/xx unknown
- 2012-09-10 CA CA2848611A patent/CA2848611A1/en not_active Abandoned
- 2012-09-10 PH PH1/2014/500456A patent/PH12014500456A1/en unknown
- 2012-09-10 US US14/344,637 patent/US10752676B2/en not_active Expired - Fee Related
- 2012-09-10 SG SG10201701055WA patent/SG10201701055WA/en unknown
- 2012-09-10 SG SG11201400193SA patent/SG11201400193SA/en unknown
- 2012-09-10 JP JP2014530307A patent/JP6152107B2/ja not_active Expired - Fee Related
- 2012-09-10 KR KR1020147010064A patent/KR20140063825A/ko not_active Withdrawn
- 2012-09-10 BR BR112014006175-0A patent/BR112014006175B1/pt not_active IP Right Cessation
- 2012-09-10 EA EA201400345A patent/EA032475B1/ru not_active IP Right Cessation
- 2012-09-10 EP EP19160911.4A patent/EP3617227A3/en not_active Withdrawn
- 2012-09-10 MX MX2014002769A patent/MX2014002769A/es unknown
- 2012-09-10 CN CN201810242539.6A patent/CN108424449A/zh active Pending
- 2012-09-10 PL PL12761789T patent/PL2758432T3/pl unknown
- 2012-09-10 HR HRP20190917TT patent/HRP20190917T1/hr unknown
- 2012-09-10 SI SI201231613T patent/SI2758432T1/sl unknown
- 2012-09-10 PE PE2014000353A patent/PE20141547A1/es not_active Application Discontinuation
- 2012-09-10 CN CN201280049537.6A patent/CN103958544B/zh not_active Expired - Fee Related
- 2012-09-10 EP EP12761789.2A patent/EP2758432B1/en active Active
- 2012-09-10 LT LTEP12761789.2T patent/LT2758432T/lt unknown
- 2012-09-10 ES ES12761789T patent/ES2729278T3/es active Active
-
2014
- 2014-02-26 IL IL231167A patent/IL231167A0/en unknown
- 2014-02-27 CL CL2014000491A patent/CL2014000491A1/es unknown
- 2014-03-07 TN TNP2014000101A patent/TN2014000101A1/en unknown
- 2014-04-15 ZA ZA2014/02760A patent/ZA201402760B/en unknown
- 2014-04-15 CO CO14082286A patent/CO6930310A2/es unknown
- 2014-04-16 EC ECSP14013316 patent/ECSP14013316A/es unknown
-
2017
- 2017-05-26 JP JP2017104698A patent/JP6603685B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-05 CY CY20191100596T patent/CY1121673T1/el unknown
- 2019-10-11 JP JP2019187271A patent/JP2020037555A/ja not_active Ceased
-
2020
- 2020-07-02 US US16/919,576 patent/US20200377578A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121673T1 (el) | Εξουδετερωση αντισωματων στις κυριες εξωτοξινες tcda και tcdb της λοιμωξης clostridium difficile | |
| CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
| CY1122478T1 (el) | Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη | |
| EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
| CY1122669T1 (el) | Σκευασματα αντισωματων αντισκληροστινης υψηλης συγκεντρωσης | |
| CY1119055T1 (el) | Αντισωματα που προσδενονται στην il-17a και στην il-17f | |
| CY1121349T1 (el) | Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| PE20171041A1 (es) | Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion | |
| EA201391389A1 (ru) | Кристаллы антител против склеростина и составы на их основе | |
| UA110470C2 (ru) | Антидот антикоагулянта | |
| EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
| CO7151488A2 (es) | Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos | |
| EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
| UY32501A (es) | Anticuerpo antagonista específico para el heterodímero alfa4-beta7 | |
| EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
| PL3702368T3 (pl) | Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klierens antygenu | |
| BR112015011518B8 (pt) | Anticorpo heterodimérico, ácido nucleico e vetor | |
| MX364327B (es) | Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22. | |
| GT201400045A (es) | Anticuerpo anti-abtcr | |
| PE20151408A1 (es) | Anticuerpos cd47 que no agotan plaquetas ni globulos rojos y metodos de uso de los mismos | |
| CR20130359A (es) | Anticuerpos del cea | |
| EA201591974A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
| EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения |